Citadel Advisors
EVLO

Citadel Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Citadel Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$322 – 15933
2022
Q4 		$322 Buy
+10
New +$396 ﹤0.01% 14693
2022
Q1 		– Sell
-1,020
Closed -$124K – 14990
2021
Q4 		$124K Sell
1,020
-7,545
-88% -$1.27M ﹤0.01% 12490
2021
Q3 		$1.21M Buy
+8,565
New +$1.7M ﹤0.01% 7665

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's EVLO Position: Q1 2023 in Review

Citadel Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 498 shares — an estimated $16K sold.

Citadel Advisors first reported a position in EVLO in Q1 2020 and held it in 8 quarters. The position peaked at $382K in Q1 2021. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • Citadel Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 498 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $16K.
  • Citadel Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • Citadel Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $382K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.